Brain atrophy in multiple sclerosis: therapeutic, cognitive and clinical impact

ABSTRACT Multiple sclerosis (MS) was always considered as a white matter inflammatory disease. Today, there is an important body of evidence that supports the hypothesis that gray matter involvement and the neurodegenerative mechanism are at least partially independent from inflammation. Gray matter...

Full description

Saved in:
Bibliographic Details
Published in:Arquivos de neuro-psiquiatria 2016-03, Vol.74 (3), p.235-243
Main Authors: Rojas, Juan Ignacio, Patrucco, Liliana, Miguez, Jimena, Cristiano, Edgardo
Format: Article
Language:English
Subjects:
atrofia cerebral
Atrophy - etiology
Atrophy - pathology
Brain - pathology
Brain Diseases - pathology
Disease Progression
esclerosis múltiple
Humans
Magnetic Resonance Imaging
Multiple Sclerosis - pathology
neurodegeneración
NEUROSCIENCES
PSYCHIATRY
Risk Factors
Severity of Illness Index
VIEW AND REVIEW
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ABSTRACT Multiple sclerosis (MS) was always considered as a white matter inflammatory disease. Today, there is an important body of evidence that supports the hypothesis that gray matter involvement and the neurodegenerative mechanism are at least partially independent from inflammation. Gray matter atrophy develops faster than white matter atrophy, and predominates in the initial stages of the disease. The neurodegenerative mechanism creates permanent damage and correlates with physical and cognitive disability. In this review we describe the current available evidence regarding brain atrophy and its consequence in MS patients.
ISSN:0004-282X
1678-4227
1678-4227
0004-282X
DOI:10.1590/0004-282X20160015